For what it's worth. Unsure whether the RSV market will be sizeable as it tends to be a mild virus, Maybe there is a market for some at risk pediatric and adults and elderly patients. At least it looks like Biota has learnt a lesson and is not doing inhalers, but rather, tablets/oral.
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585
'We are encouraged by the data from this first-in-man study and, based on these favorable results, we have commenced dosing in a Phase 1 multiple ascending dose (MAD) study of BTA585 in healthy volunteers. We anticipate top-line data from the MAD trial in the first half of 2016,' stated , PhD, president and chief executive officer of Biota. 'Given the significant demand for a new modality to treat potentially life-threatening RSV infections in the pediatric, elderly, and immunocompromised patient populations, we are pleased with the progress we've made with BTA585 and look forward to building upon the momentum by initiating a Phase 2 trial in the first half of 2016.'
The blinded, placebo-controlled SAD study, which was conducted in under an Investigational New Drug Application (IND), evaluated the safety and pharmacokinetics (PK) of five oral doses of BTA585 (50, 100, 200, 400, and 500 mg) in healthy volunteers. In addition, the 100 mg cohort included an evaluation of the effect of food on the PK profile of BTA585. Each of the dose cohorts consisted of seven subjects that received BTA585 and three that received placebo. Overall, there was low incidence of AEs with BTA585 treatment. AEs occurring in more than two BTA585-treated subjects included headache, nausea, and chromaturia. In the fasted subjects, pharmacokinetic data demonstrated that doses ≥ 100 mg achieved BTA585 plasma levels that exceeded the mean EC of RSV clinical isolates for 24 hours. represents the concentration of drug that is required for 50% inhibition of viral replication in vitro. The BTA585 plasma C was rapidly achieved at approximately one hour following oral dosing and the half-life (T) was approximately five to six hours. Additionally, dosing of BTA585 with a high fat meal did not adversely affect the PK.
(GLOBE NEWSWIRE) -- (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it completed an initial Phase 1 single ascending dose (SAD) trial of BTA585, an oral respiratory syncytial virus (RSV) fusion inhibitor in development for the treatment and prevention of RSV infections. Top-line data demonstrated that BTA585 was generally well tolerated at all dose levels; there were no serious adverse events (AEs), and no drug-related clinically-significant changes in ECGs or clinical laboratory values were observed. The Company plans to present the full data from this trial at an upcoming scientific meeting in 2016.
'We are encouraged by the data from this first-in-man study and, based on these favorable results, we have commenced dosing in a Phase 1 multiple ascending dose (MAD) study of BTA585 in healthy volunteers. We anticipate top-line data from the MAD trial in the first half of 2016,' stated , PhD, president and chief executive officer of Biota. 'Given the significant demand for a new modality to treat potentially life-threatening RSV infections in the pediatric, elderly, and immunocompromised patient populations, we are pleased with the progress we've made with BTA585 and look forward to building upon the momentum by initiating a Phase 2 trial in the first half of 2016.'
The blinded, placebo-controlled SAD study, which was conducted in under an Investigational New Drug Application (IND), evaluated the safety and pharmacokinetics (PK) of five oral doses of BTA585 (50, 100, 200, 400, and 500 mg) in healthy volunteers. In addition, the 100 mg cohort included an evaluation of the effect of food on the PK profile of BTA585. Each of the dose cohorts consisted of seven subjects that received BTA585 and three that received placebo. Overall, there was low incidence of AEs with BTA585 treatment. AEs occurring in more than two BTA585-treated subjects included headache, nausea, and chromaturia. In the fasted subjects, pharmacokinetic data demonstrated that doses ≥ 100 mg achieved BTA585 plasma levels that exceeded the mean EC of RSV clinical isolates for 24 hours. represents the concentration of drug that is required for 50% inhibition of viral replication in vitro. The BTA585 plasma C was rapidly achieved at approximately one hour following oral dosing and the half-life (T) was approximately five to six hours. Additionally, dosing of BTA585 with a high fat meal did not adversely affect the PK.
- See more at: http://www.noodls.com/view/4303FAD4532E50928D29F5EBBF388F0A8C9712DF#sthash.Qt7oyTUD.dpuf
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585 - See more at: http://www.noodls.com/view/4303FAD4532E50928D29F5EBBF388F0A8C9712DF#sthash.Qt7oyTUD.dpuf
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585 - See more at: http://www.noodls.com/view/4303FAD4532E50928D29F5EBBF388F0A8C9712DF#sthash.Qt7oyTUD.dpuf
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585 - See more at: http://www.noodls.com/view/4303FAD4532E50928D29F5EBBF388F0A8C9712DF#sthash.Qt7oyTUD.dpuf
BTA Price at posting:
57.0¢ Sentiment: Hold Disclosure: Held
